Dental biofilms

01Key questions

02The Oral Biofilm Ecosystem

• ~700 bacterial species colonize the human mouth; supragingival plaque, subgingival biofilm, and tongue coating are distinct ecosystems
• Dental plaque is the archetype of the four-stage biofilm cycle (attachment → EPS → maturation → dispersion) described in Biofilms Overview
• Subgingival biofilm (below the gumline, anaerobic) drives periodontitis: a chronic, polymicrobial, biofilm-protected infection of the tooth-supporting tissues
• Keystone pathogen concept: Porphyromonas gingivalis is present in low abundance but remodels the whole community toward dysbiosis — it subverts host immunity (complement, IL-8) so the commensal biofilm becomes inflammatory

Periodontitis Prevalence

Severe periodontitis affects ~10-15% of adults globally (WHO); mild-moderate disease affects the majority over 40. It is a stealth infection by this library's definition — chronic, culture-negative in routine care, rarely painful until advanced, and systemically ignore. It belongs on the Stealth Pathogens watchlist as much as any tick-borne organism.

03The Alzheimer's Link — Evidence and Its Failure

The Case (Mechanistic)

Dominy et al. (Science Advances, 2019, PMID 30988396) — the foundational paper:

• P. gingivalis DNA and gingipain antigens found in AD post-mortem brains, significantly more frequent than controls
• Gingipains (cysteine proteases Kgp, RgpA, RgpB) are the virulence factors; they are neurotoxic, degrade tau-protection pathways, and promote Aβ42 production in vivo
• Oral gingipain inhibitor (COR388/atuzaginstat) blocked neurodegeneration, reduced brain bacterial load and Aβ42 in mice
• Proposed routes into brain: hematogenous spread during periodontal bacteremia, infected monocytes, peripheral nerve pathways, and outer-membrane vesicles

Subsequent reviews (Huang et al., Front Immunol 2025; Sarmiento-Ordóñez et al., 2025, PMC12043021; MDPI Life 2025) add: gingipain-mediated BBB disruption, LPS-driven neuroinflammation, tau hyperphosphorylation, and epidemiological associations between periodontitis and AD risk.

The Crash (Clinical)

GAIN trial (Cortexyme, NCT03823404) — the direct test of the causal hypothesis:

• Phase 2/3, randomized double-blind placebo-controlled, n=643, mild-moderate AD, 48 weeks
• Atuzaginstat 40mg or 80mg BID — orally bioavailable, BBB-penetrant gingipain inhibitor
• Result: failed both co-primary endpoints (ADAS-Cog11, ADCS-ADL) in October 2021
• Safety: hepatotoxicity signal → FDA clinical hold (Jan 2022) → development program suspended

Interpretation for this library: the human causal test failed. Remaining live options: (a) gingipains contribute to AD initiation decades before symptoms — undetectable in a 48-week symptomatic trial; (b) the association is reverse causation or confounding (poor oral hygiene as early dementia symptom); (c) real but small contribution. Rate the P. gingivalis→AD hypothesis plausible, unproven, no pharmacological shortcut available. Prevention (below) remains rational on other grounds regardless.

04Cardiovascular Disease

Mechanistic reviews (Wang et al., Int J Dent 2025, PMC12398414; Clinical review Biomedicines 2025):

• Pathways: periodontal bacteremia → endothelial dysfunction; systemic IL-6/CRP elevation; bacterial DNA/LPS in atherosclerotic plaque (P. gingivalis and Aggregatibacter actinomycetemcomitans DNA detected in plaque samples); autoimmunity to heat-shock proteins
• Essa et al. (Br Dent J, 2025): global federated real-world database analysis — T2D + periodontitis carries increased CV risk beyond T2D alone
• Meta-analyses of cohort data show periodontitis associated with incident ASCVD, stroke (Dewan et al., Dent Med Probl 2024), and dyslipidemia (BMC Oral Health 2024)

Evidence grade: associative with strong mechanism, causation unproven. Periodontal-treatment→CV-outcome RCTs do not exist (and may never — required n and duration are prohibitive). Treat as terrain optimization, not established risk-factor treatment.

05Diabetes — The Strongest Causal Evidence

The bidirectional periodontitis-diabetes axis has actual intervention trials:

• Meta-analyses of RCTs: non-surgical periodontal therapy reduces HbA1c by ~0.3-0.4% (mean difference −0.34%, 95% CI −0.43 to −0.26) in T2D patients with periodontitis — comparable to adding a second-line oral agent
• Baseline HbA1c matters: systematic review (Adv Ther 2021) — in patients with baseline HbA1c >9%, periodontal therapy reduced HbA1c by WMD −1.20% (95% CI −1.68 to −0.72)
• Oliveira et al. (J Clin Periodontol 2023): 6-month follow-up meta-regression confirms durability of effect
• Umezaki et al. 2025 (PMC11893427): HbA1c and CRP both fall — consistent with infection-burden mechanism, not just oral hygiene theater
• Diabetes also impairs periodontal defense (AGE-mediated, neutrophil dysfunction) — the relationship is genuinely bidirectional

Evidence grade: RCT-backed. This is the strongest oral-systemic link in the file. Any T2D or prediabetic protocol that ignores periodontal status is incomplete.

06The Nitrate-Nitrite-NO Pathway (Why Antiseptic Mouthwash Backfires)

The oral cavity is not just a threat — it is a metabolic organ:

1. Dietary nitrate (leafy greens, beetroot) is absorbed, concentrated in salivary glands, secreted into the mouth
2. Tongue-dwelling nitrate-reducing bacteria (predominantly Neisseria, Rothia, Veillonella, Actinomyces spp.) convert nitrate → nitrite
3. Swallowed nitrite → gastric and systemic nitric oxide — a major NO source when endothelial NO synthase declines with age

Antiseptic mouthwash breaks step 2:

• Chlorhexidine 0.12-0.2% destroys up to ~90-94% of oral nitrate-reducing bacteria
• Crossover studies: 7-day CHX → oral nitrite −90%, plasma nitrite −25%, systolic/diastolic BP +2-3.5 mmHg (correlating with nitrite fall)
• Systematic review/meta-analysis (2025, PMC13309218): twice-daily CHX significantly raises systolic BP after 1 week; nitrate-reducing taxa recover after cessation
• Older hypertensive patients on PDE5 inhibitors or nitrates have amplified reasons to preserve this pathway
• Emerging direction (U Exeter group): nitrate as an oral prebiotic — beetroot juice shifts oral ecology (↓Prevotella) and supports nitrite production

Practical inversion: the biohacker default of daily antiseptic rinse is, on current evidence, mildly harmful for vascular health. Reserve CHX for short therapeutic courses (e.g. post-surgical 1-2 weeks); never chronic.

07Practical Context

Swipe table →

On rapamycin/mTOR caution: any rapa-containing longevity protocol (see Rapamycin Dosing Protocols) with impaired wound healing needs aggressive dental stabilization before starting — dental procedures during rapa courses carry wound-healing and infection risks flagged in the longevity literature.

08Evidence Summary

Swipe table →

09Open Questions

1. Does aggressive periodontal therapy in mid-life change AD or CVD incidence? (No trial; 20+ year horizon — watch registry-data natural experiments.)
2. Do gingipain inhibitors with better safety (COR588 successors) ever re-enter testing — perhaps in prevention rather than symptomatic AD?
3. Which tongue taxa are the load-bearing nitrate reducers, and can they be deliberately seeded (oral probiotics beyond S. salivarius K12)?
4. Interaction: does rapamycin-induced immunomodulation change periodontal disease trajectory (case reports of gingival overgrowth on mTOR inhibitors in transplant)?

10Connections

11Sources

1. PubMed 30988396PubMed 30988396
2. PMC12043021PMC12043021
3. NCT03823404NCT03823404
4. PMC12398414PMC12398414
5. PMC11893427PMC11893427
6. PMC13309218PMC13309218

12Entry history

Heretic informs and never prescribes. Where amounts appear, they describe what published studies used. Talk to a qualified clinician before acting on anything here.